142 related articles for article (PubMed ID: 36399194)
21. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Konopleva MY; Röllig C; Cavenagh J; Deeren D; Girshova L; Krauter J; Martinelli G; Montesinos P; Schäfer JA; Ottmann O; Petrini M; Pigneux A; Rambaldi A; Recher C; Rodriguez-Veiga R; Taussig D; Vey N; Yoon SS; Ott M; Muehlbauer S; Beckermann BM; Catalani O; Genevray M; Mundt K; Jamois C; Fenaux P; Wei AH
Blood Adv; 2022 Jul; 6(14):4147-4156. PubMed ID: 35413116
[TBL] [Abstract][Full Text] [Related]
22. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
23. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
24. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Robles C; Kim KM; Oken MM; Bennett JM; Letendre L; Wiernik PH; O'Connell MJ; Cassileth PA
Leukemia; 2000 Aug; 14(8):1349-53. PubMed ID: 10942228
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Martínez-Cuadrón D; Montesinos P; Oriol A; Salamero O; Vidriales B; Bergua J; Herrera P; Vives S; Sanz J; Carpio C; Rodríguez-Veiga R; Moscardó F; Sanz MA
Ann Hematol; 2014 Jan; 93(1):43-6. PubMed ID: 24081577
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
28. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract][Full Text] [Related]
29. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Laloi L; Billotey NC; Dumas PY; Paul F; Villate A; Simand C; Fornecker L; Puisset F; Bertoli S; Simonet MB; Laribi K; Houyou D; Santagostino A; Michel C; Guepin GR; Guerineau E; Tabrizi R; Hunault M; Giltat A; Kaphan E; Bulabois C; Cartet E; Rocher C; Lachenal F; Morisset S; Récher C; Pigneux A; Belhabri A; Michallet M; Michallet AS
Cancer Med; 2023 Mar; 12(6):7175-7181. PubMed ID: 36482507
[TBL] [Abstract][Full Text] [Related]
30. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
31. A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Mussai F; De Santo C; Cheng P; Thomas IF; Ariti C; Upton L; Scarpa U; Stavrou V; Sydenham M; Burnett AK; Knapper SK; Mehta P; McMullin MF; Copland M; Russell NH; Dennis M
Br J Haematol; 2023 Mar; 200(5):573-578. PubMed ID: 36413792
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.
Sekeres MA; Lancet JE; Wood BL; Grove LE; Sandalic L; Sievers EL; Jurcic JG
Haematologica; 2013 Jan; 98(1):119-28. PubMed ID: 22801961
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Yamauchi T; Yoshida C; Usuki K; Takada S; Matsumura I; Dobashi N; Miyazaki Y; Miyamoto T; Iida H; Asou N; Kuroda J; Ichikawa S; Komatsu N; Mendes W; Honda H; Okubo S; Kurokawa M; Jiang Q; Wei A; Ishizawa K
Jpn J Clin Oncol; 2021 Aug; 51(9):1372-1382. PubMed ID: 34322703
[TBL] [Abstract][Full Text] [Related]
34. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M; Burnett A; Hills R; Thomas I; Ariti C; Severinsen MT; Hemmaway C; Greaves P; Clark RE; Copland M; Russell N;
Br J Haematol; 2021 Jul; 194(2):298-308. PubMed ID: 33961292
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon R; Maycock S; Jackson A; Fox S; Freeman S; Craddock C; Thomas C; Homer E; Leahy J; Mamwell A; Potter N; Russell N; Wei A; Ommen HB; Hemmaway C; Knapper S; Billingham L
BMC Cancer; 2022 Nov; 22(1):1174. PubMed ID: 36376888
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
37. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Yoshida C; Kondo T; Ito T; Kizaki M; Yamamoto K; Miyamoto T; Morita Y; Eto T; Katsuoka Y; Takezako N; Uoshima N; Imada K; Ando J; Komeno T; Mori A; Ishikawa Y; Satake A; Watanabe J; Kawakami Y; Morita T; Taneike I; Nakayama M; Duan Y; Garbayo Guijarro B; Delgado A; Llamas C; Kiyoi H
Int J Hematol; 2022 Jul; 116(1):89-101. PubMed ID: 35394258
[TBL] [Abstract][Full Text] [Related]
38. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Brackman D; Eckert D; Menon R; Salem AH; Potluri J; Smith BD; Wei AH; Hayslip J; Miles D; Mensing S; Gopalakrishnan S; Zha J
Hematol Oncol; 2022 Apr; 40(2):269-279. PubMed ID: 35043428
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Qin Y; Kuang P; Liu T
Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
